the beneficial antiarrhythmic and antifibrillatory actions of flecainide affect only the arrhythmias resulting from transmural necrosis of the myocardium ( `` '' in-hospital arrhythmias '' '' , 2nd-phase arrhythmias '' '' ) , whereas the incidence of early ventricular arrhythmias , especially ventricular fibrillation occurring in the very inception of myocardial ischaemia ( `` '' pre-hospital arrhythmias '' '' , `` '' 1st-phase arrhythmias '' '' ) is not prevented .
C0016229
flecainide
C0003811
arrhy